@inbook{raza_merhi_relecom_fernandes_inchakalody_rahman zar gul_uddin_ussama al homsi_dermime_2021, 
  title={Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer}, 
  DOI={10.5772/intechopen.96494}, 
  abstractNote={<jats:p>Immune checkpoint inhibitors (ICIs) have been approved as first or second line therapy in a large group of cancers. However, the observation of potentially long-lasting responses was restricted to limited subset of patients. Efforts have been made to identify predictive factors of response to ICIs in order to select eligible patients and to avoid exposing non-responding patients to treatment side effects. Although several biomarkers have been identified, their predictive potential remains unsatisfactory. One promising emerging approach is to focus on dynamic biomarkers to directly characterize the response and, more importantly, to identify those patients presenting an immune response failure. Several studies have shown a strong correlation between specific circulating immune cell subsets and tumor immune infiltrates. Moreover, liquid biomarkers including soluble immune checkpoint molecules have potential in predicting the modulation of the immune response under immune checkpoint blockade. In this chapter, we will discuss current advances in the study of circulatory and intra-tumoral dynamic biomarkers as predictors of responses to ICIs therapy in cancer.</jats:p>}, 
  publisher={IntechOpen}, 
  author={Raza, Afsheen and Merhi, Maysaloun and Relecom, Allan and Fernandes, Queenie and Inchakalody, Varghese and Rahman Zar Gul, Abdul and Uddin, Shahab and Ussama Al Homsi, Mohammed and Dermime, Said}, 
  year={2021}, 
  month={Mar}
  }